In xenograft mouse models of advanced ovarian, hepatocellular, and pancreatic carcinomas with glypican-3 or MSLN expression, these cytokine-secreting CAR T cells showed enhanced antitumor activity, higher cell levels in peripheral blood, and increased infiltrating CAR T cells in tumor tissue compared to non-cytokine-secreting CAR T cells, and significantly suppressed tumor growth (79). This evidence concerns the gene GPC3 and neoplasm.